Skip to main content
Clinical Trials/NCT02290548
NCT02290548UnknownNot Applicable

Effect of High-flow Nasal Oxygen vs Standard Oxygen Therapy on Extubation Outcome With High Risk of Extubation Failure in Medical ICU Patients

Mackay Memorial Hospital1 site in 1 country400 target enrollmentStarted: December 2014Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Enrollment
400
Locations
1
Primary Endpoint
reintubation rate

Study Overview

Brief Summary

The purpose of this study is to determine whether high flow nasal cannula is effective in lowering the reintubation rate after extubation for high risk patients in medical intensive care unit

Detailed Description

The study hypothesis is that Optiflow may reduce the extubation failure rate for high risk patients in medical intensive care unit.In the intervention group, patients fulfilling inclusion criteria and not presenting any of the exclusion criteria will receive high-flow nasal cannula (Optiflow Airvo2, Fisher & Paykel Healthcare Ltd., New Zealand) after extubation. The oxygen concentration (FiO2) will be set to reach an oxygenation target similar to control patients (see below), while the gas flow rate will be set at 50 L/min.In the control group, patients fulfilling inclusion criteria and not presenting any of the exclusion criteria will receive standard oxygen therapy including nasal cannula or oxygen mask after extubation. The FiO2 will be set to obtain a arterial oxygen saturation (SpO2) between 92% and 98% (or between 88% and 95% in hypercapnic patients). NIPPV or intubation will be applied in both group if respiratory distress noted. High flow nasal cannula will be tried before NIPPV or intubation in the control group patients.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double (Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to 95 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients mechanically ventilated for > 48 hours and at least one of the following:
  • > 65 y/o
  • Cardiac failure as the primary indication of mechanical ventilation
  • Bronchiectasis
  • Old pulmonary tuberculosis with destructive lung
  • Chronic renal failure
  • Neuromuscular disease
  • BMI > 30
  • Inability to manage respiratory secretions

Exclusion Criteria

  • Presence of tracheostomy
  • Recent facial trauma
  • Active gastro-intestinal bleeding
  • Planned NIPPV support after extubation

Outcomes

Primary Outcomes

reintubation rate

Time Frame: 72 hours after extubation

Secondary Outcomes

  • Need for Non-Invasive Ventilation(at day 28 after inclusion in the study)
  • ICU readmission rate due to respiratory failure(at day 28 after inclusion in the study)
  • ICU mortality rate(at day 28 after inclusion in the study)
  • ICU length of stay(at day 28 after inclusion in the study)
  • Hospital mortality(at day 28 after inclusion in the study)
  • Hospital length of stay(at day 28 after inclusion in the study)
  • Nosocomial pneumonia rate(at day 28 after inclusion in the study)
  • Desaturation ( SaO2< 90%)(72 hours after extubation)
  • Severe hypoxemia (PaO2/Fraction of inspired O2 < 200)(Time Frame: 72 hours after extubation)
  • hypercapnia (PaCO2 > 50)(72 hours after extubation)
  • respiratory acidosis (arterial pH < 7.30)(72 hours after extubation)
  • severe tachypnea (>40/min)(72 hours after extubation)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials